Europe Posts 0.1% Economic Growth In Second Quarter
The European Union (EU) has posted better-than-expected 0.1% growth for the year’s second quarter, according to data from statistics agency Eurostat.
Economists surveyed by the Reuters news agency had anticipated flat growth across Europe during the period, following a 0.6% annualized expansion in the first quarter of 2025.
Tariffs remain a concern for European countries as U.S. President Donald Trump continues to threaten import duties on the trading bloc.
Like most regions of the world, Europe has struggled with uncertainty amid ongoing trade negotiations and threats of high tariffs by President Trump.
Some higher sectoral tariffs, including on automobiles and steel, have come into effect.
In the past week, the European Union agreed to a trade framework with the U.S., which includes 15% tariffs being imposed on goods and services from the bloc.
European bond yields were little changed after the data on Q2 gross domestic product (GDP) was released, with both the French and German 10-year bonds up by less than one basis point.
Separate data released on July 30 showed that Europe’s largest economy, Germany, shrank by 0.1% in the second quarter from the previous three months.
The Q2 figure for Germany represents a sharp downturn from a revised 0.3% expansion in the year’s first quarter.
The German economy has been dragged lower as investments in machinery and equipment, as well as construction, have declined in recent months.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


